Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2

Status

Unknown 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Sarcoma 1

Conditions

Carcinoma, Basal Cell 4Melanoma 2Sarcoma, Kaposi 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × daromun × Dermatologic × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07227870 2026-03-09

L19IL2/TNF in Patients With Basal Cell Carcinoma

Philogen S.p.A.

Phase 2 Not yet recruiting
92 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT06284590 2024-10-26

INTACT/MeRCI

Philogen S.p.A.

Phase 2 Recruiting
162 enrolled
Dermatologic

Melanoma

NCT04362722 2023-10-10

DUNCAN

Philogen S.p.A.

Phase 2 Unknown
40 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell

NCT05329792 2023-10-06

IntriNSiC

Philogen S.p.A.

Phase 2 Unknown
70 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Sarcoma, Kaposi, Carcinoma, Merkel Cell

NCT02076633 2015-05-27

Intratumoral Administration of L19IL2/L19TNF

Philogen S.p.A.

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡